Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$50.88 USD
+0.89 (1.78%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $50.89 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRAX 50.88 +0.89(1.78%)
Will PRAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRAX
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
Other News for PRAX
Praxis Precision Medicines management to meet virtually with Piper Sandler
Praxis Precision Medicines management to meet virtually with Piper Sandler
Praxis Precision Medicines initiated with bullish view at Needham
Wall Street Analysts Are Bullish on Top Healthcare Picks
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst